Results: 112

Incidencia de eventos cardiovasculares mayores asociada a la suspensión de doble terapia antiagregante en pacientes con enfermedad coronaria e implante de stent

Rev. colomb. cardiol; 24 (4), 2017
Resumen Objetivo: Determinar el riesgo de presentar eventos cardiovasculares mayores en pacientes con síndrome coronario agudo e implante de stent, que suspendieron la doble terapia antiagregante antes de un año de tratamiento. Métodos: Estudio analítico de pacientes con síndrome coronario agudo ...

Duración de la antiagregación dual postintervencionismo percutáneo

Rev. colomb. cardiol; 24 (3), 2017
Resumen Introducción: Con el uso de stents medicados de primera generación, el riesgo de trombosis es de 1,9% a 18 meses, con consecuencias que suelen ser graves y potencialmente fatales. La antiagregación doble, que previene tal efecto, conlleva un riesgo de sangrado que se incrementa según la dur...

Spontaneous carotid dissection

Summary Carotid dissection is a rare occurrence but it is the main cause of stroke in individuals aged less than 45 years, and can be the etiology in up to 25% of strokes in young adults. We report a case with classic image of ying yang on vascular ultrasound, which was treated according to the best avai...

Evidencias para el uso combinado de ácido acetilsalicílico (aspirina) y clopidogrel en síndromes coronarios agudos

Invest. clín; 58 (1), 2017
Las enfermedades tromboembólicas siguen siendo una de las causas más importantes de morbilidad y mortalidad en todo el mundo. El mecanismo fisiopatológico subyacente en los síndromes coronarios agudos es la trombosis coronaria. Por eso, la base de su tratamiento se ha centrado en los fármacos antipl...

The effectiveness of aspirin for migraine prophylaxis: a systematic review

Säo Paulo med. j; 135 (1), 2017
ABSTRACT CONTEXT AND OBJECTIVE: Many researchers have suggested that aspirin prevents migraines. However, the evidence is unclear. The aim of this study was to analyze the available evidence on the effect of aspirin as a migraine prophylactic. DESIGN AND SETTING: Systematic review, conducted at the P...

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients

Braz. j. med. biol. res; 50 (1), 2017
Clopidogrel and aspirin are the most commonly used medications worldwide for dual antiplatelet therapy after percutaneous coronary intervention. However, clopidogrel hyporesponsiveness related to gene polymorphisms is a concern. Populations with higher degrees of genetic admixture may have increased prev...

Stroke Prevention in Atrial Fibrillation: Focus on Latin America

Arq. bras. cardiol; 107 (6), 2016
Abstract Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with an estimated prevalence of 1-2% in North America and Europe. The increased prevalence of AF in Latin America is associated with an ageing general population, along with poor control of key risk factors, including hype...

Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients

Arch. cardiol. Méx; 86 (4), 2016
Abstract Objective Drug inhibition of platelet P2Y12 adenosine diphosphate receptor has reduced the incidence of adverse cardiovascular events after percutaneous coronary interventions. The analysis of the phosphorylation status of vasodilator-stimulated phosphoprotein by flow cytometry has shown a pred...

Efecto del 27- hidroxicolesterol en la acción antiplaquetaria de estradiol en mujeres postmenopáusicas

Rev. méd. Chile; 144 (11), 2016
Background: The decline of estrogen levels increases cardiovascular risk in women. Platelets express estrogen receptors and 17β-estradiol- (E2) can produce a protective effect on thrombus formation. The hydroxylation of cholesterol generates several sterols and 27-hydroxycholesterol (27HC) predomina...

In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study

Arq. bras. cardiol; 107 (5), 2016
Abstract Background: Despite successful opening of culprit coronary artery, myocardial reperfusion does not always follows primary percutaneous coronary intervention (PPCI). Glycoprotein IIb/IIIa inhibitors are used in the treatment of no-reflow (NR), but their role to prevent it is unproven. Objective...